首页 > 最新文献

Scandinavian Journal of Infectious Diseases最新文献

英文 中文
Mycobacterium bovis meningitis in young Nigerian-born male. 尼日利亚出生的年轻男性患牛分枝杆菌脑膜炎。
Pub Date : 2014-10-01 Epub Date: 2014-08-19 DOI: 10.3109/00365548.2014.937455
Daniel Faurholt-Jepsen, Troels Lillebaek, Ming-Yuan Nielsen, Susanne Dam Nielsen

In Denmark, tuberculous meningitis is rare. Central nervous system (CNS) involvement with Mycobacterium bovis is even rarer and has only been seen three times since 1992. We present a case of M. bovis meningitis in a previously healthy young Nigerian-born male, who had been exposed to unpasteurized dairy products in Nigeria but had no known contact with larger mammals. Before the development of meningitis, the patient had several contacts with the health system due to fever and non-specific symptoms. Finally, upon hospital admission, the patient was diagnosed with M. tuberculosis complex meningitis and treated empirically. After 13 days he was discharged without neurological sequelae. Later, the culture revealed M. bovis and treatment was adjusted accordingly.

在丹麦,结核性脑膜炎很少见。牛分枝杆菌累及中枢神经系统(CNS)更为罕见,自1992年以来仅见过3次。我们报告一例既往健康的尼日利亚出生的年轻男性患牛分枝杆菌脑膜炎,他曾在尼日利亚接触过未经巴氏消毒的乳制品,但没有接触过大型哺乳动物。在出现脑膜炎之前,该患者因发烧和非特异性症状与卫生系统有过几次接触。最后,在入院时,患者被诊断为结核分枝杆菌复合脑膜炎并进行经验治疗。13天后出院,无神经系统后遗症。后来,培养发现牛分枝杆菌,并相应地调整治疗。
{"title":"Mycobacterium bovis meningitis in young Nigerian-born male.","authors":"Daniel Faurholt-Jepsen,&nbsp;Troels Lillebaek,&nbsp;Ming-Yuan Nielsen,&nbsp;Susanne Dam Nielsen","doi":"10.3109/00365548.2014.937455","DOIUrl":"https://doi.org/10.3109/00365548.2014.937455","url":null,"abstract":"<p><p>In Denmark, tuberculous meningitis is rare. Central nervous system (CNS) involvement with Mycobacterium bovis is even rarer and has only been seen three times since 1992. We present a case of M. bovis meningitis in a previously healthy young Nigerian-born male, who had been exposed to unpasteurized dairy products in Nigeria but had no known contact with larger mammals. Before the development of meningitis, the patient had several contacts with the health system due to fever and non-specific symptoms. Finally, upon hospital admission, the patient was diagnosed with M. tuberculosis complex meningitis and treated empirically. After 13 days he was discharged without neurological sequelae. Later, the culture revealed M. bovis and treatment was adjusted accordingly.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.937455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32594638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. 在成年hiv -1感染患者中,两剂aso3佐剂大流行性H1N1流感疫苗并没有增强保护性抗体效价的持久性。
Pub Date : 2014-09-01 Epub Date: 2014-07-08 DOI: 10.3109/00365548.2014.922695
Markus Bickel, Corinna Lais, Imke Wieters, Frank P Kroon, Hans Wilhelm Doerr, Eva Herrmann, Hans Reinhard Brodt, Oliver Jung, Regina Allwinn, Christoph Stephan

The immune response after influenza vaccination is impaired in HIV-infected individuals and can be enhanced by a second dose. The durability of the antibody protection and its clinical benefit is not known. We investigated clinical symptoms and antibody titres against H1N1 influenza A following no dose, 1 dose, or 2 doses of an ASO3-adjuvanted H1N1 vaccine in HIV-infected patients. Seroprotection was found in 7.9%, 52.2%, and 57.3% of patients who received no dose, 1 dose, and 2 doses of the vaccine, respectively (p-value for group comparison < 0.001), after a median of 8.2 ± 1.6 months. Clinical symptoms suggestive of an influenza-like illness were slightly more frequently reported in the unvaccinated group. Vaccinated HIV-infected patients were more likely to be seroprotected at follow-up, but there was no difference comparing those who had received 1 or 2 doses of the vaccine.

艾滋病毒感染者接种流感疫苗后的免疫反应受损,可通过第二次接种增强。抗体保护的持久性及其临床益处尚不清楚。我们调查了hiv感染患者在无剂量、1剂量或2剂量aso3佐剂H1N1疫苗后的临床症状和抗H1N1流感抗体滴度。在中位时间为8.2±1.6个月后,未接种疫苗、接种1剂疫苗和接种2剂疫苗的患者中,分别有7.9%、52.2%和57.3%的患者出现血清保护(组间比较p值< 0.001)。提示流感样疾病的临床症状在未接种疫苗组中报告的频率略高。在随访中,接种过艾滋病毒的患者更有可能得到血清保护,但与接种过1剂或2剂疫苗的患者相比,没有差异。
{"title":"Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.","authors":"Markus Bickel,&nbsp;Corinna Lais,&nbsp;Imke Wieters,&nbsp;Frank P Kroon,&nbsp;Hans Wilhelm Doerr,&nbsp;Eva Herrmann,&nbsp;Hans Reinhard Brodt,&nbsp;Oliver Jung,&nbsp;Regina Allwinn,&nbsp;Christoph Stephan","doi":"10.3109/00365548.2014.922695","DOIUrl":"https://doi.org/10.3109/00365548.2014.922695","url":null,"abstract":"<p><p>The immune response after influenza vaccination is impaired in HIV-infected individuals and can be enhanced by a second dose. The durability of the antibody protection and its clinical benefit is not known. We investigated clinical symptoms and antibody titres against H1N1 influenza A following no dose, 1 dose, or 2 doses of an ASO3-adjuvanted H1N1 vaccine in HIV-infected patients. Seroprotection was found in 7.9%, 52.2%, and 57.3% of patients who received no dose, 1 dose, and 2 doses of the vaccine, respectively (p-value for group comparison < 0.001), after a median of 8.2 ± 1.6 months. Clinical symptoms suggestive of an influenza-like illness were slightly more frequently reported in the unvaccinated group. Vaccinated HIV-infected patients were more likely to be seroprotected at follow-up, but there was no difference comparing those who had received 1 or 2 doses of the vaccine.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.922695","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32489750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High bacterial loads of Ureaplasma may be associated with non-specific cervicitis. 脲原体细菌负荷高可能与非特异性宫颈炎有关。
Pub Date : 2014-09-01 Epub Date: 2014-07-14 DOI: 10.3109/00365548.2014.922696
Lu Liu, Guojun Cao, Zhen Zhao, Fang Zhao, Yanqun Huang

Background: Ureaplasma parvum and Ureaplasma urealyticum are commonly found in the cervix of women with non-chlamydial and non-gonococcal cervicitis or non-specific cervicitis (NSC). However their contribution to the aetiology of NSC is controversial.

Methods: U. parvum and U. urealyticum were identified and quantified in cervical swabs collected from 155 women with NSC and 312 controls without NSC, using real-time PCR. The relative bacterial quantification was then calculated using the Ureaplasma copy number divided by the number of host cells; this is important for the correction of bias linked to the number of cells harvested in different swabs.

Results: Ureaplasma was detected in 58.7% (91/155) of NSC patients: U. parvum in 30.3%, U. urealyticum in 16.1%, and mixed infection in 12.3%. It was also detected in 54.5% (170/312) of controls: U. parvum in 33.0%, U. urealyticum in 11.5%, and mixed infection in 9.9%. There were no significant differences for U. parvum, U. urealyticum, or mixed infection between the 2 groups (p > 0.05). However, both biovars were present at higher concentrations in NSC patients than in controls (p < 0.05). Using >10 copies/1000 cells as a reference, the positive rate of U. parvum in NSC patients was 16.1%, significantly higher than that in controls at 5.1% (relative risk 3.145, p < 0.05); positive rates of U. urealyticum in NSC patients and controls were 28.4% and 8.7%, respectively, with a statistically significant difference (relative risk 3.131, p < 0.05).

Conclusions: Ureaplasma can adhere to host cells, colonize, internalize, and subsequently produce pathological lesions. A high density of Ureaplasma in the cervix may be associated with the aetiology of NSC.

背景:细小脲原体和解脲原体常见于非衣原体和非淋球菌性宫颈炎或非特异性宫颈炎(NSC)妇女的宫颈。然而,他们对NSC病因学的贡献是有争议的。方法:采用实时荧光定量PCR方法,对155例NSC患者和312例非NSC患者宫颈拭子中细小乌菌和解脲乌菌进行鉴定和定量。然后用脲原体拷贝数除以宿主细胞数计算相对细菌数量;这对于纠正与不同拭子中收获的细胞数量相关的偏差非常重要。结果:58.7%(91/155)的NSC患者检出脲原体,其中细小脲原体占30.3%,解脲原体占16.1%,混合感染占12.3%。对照组检出率为54.5%(170/312),其中细小乌菌检出率为33.0%,解脲乌菌检出率为11.5%,混合检出率为9.9%。两组间细小乌菌、解脲乌菌及混合感染的发生率差异均无统计学意义(p > 0.05)。然而,两种生物制剂在NSC患者中的浓度均高于对照组(p < 0.05)。以>10拷贝/1000细胞为对照,NSC患者中细小乌菌阳性率为16.1%,显著高于对照组的5.1%(相对危险度3.145,p < 0.05);NSC患者与对照组解脲菌阳性率分别为28.4%、8.7%,差异有统计学意义(相对危险度3.131,p < 0.05)。结论:脲原体可粘附于宿主细胞,定植、内化并产生病理病变。宫颈内高密度的脲原体可能与NSC的病因有关。
{"title":"High bacterial loads of Ureaplasma may be associated with non-specific cervicitis.","authors":"Lu Liu,&nbsp;Guojun Cao,&nbsp;Zhen Zhao,&nbsp;Fang Zhao,&nbsp;Yanqun Huang","doi":"10.3109/00365548.2014.922696","DOIUrl":"https://doi.org/10.3109/00365548.2014.922696","url":null,"abstract":"<p><strong>Background: </strong>Ureaplasma parvum and Ureaplasma urealyticum are commonly found in the cervix of women with non-chlamydial and non-gonococcal cervicitis or non-specific cervicitis (NSC). However their contribution to the aetiology of NSC is controversial.</p><p><strong>Methods: </strong>U. parvum and U. urealyticum were identified and quantified in cervical swabs collected from 155 women with NSC and 312 controls without NSC, using real-time PCR. The relative bacterial quantification was then calculated using the Ureaplasma copy number divided by the number of host cells; this is important for the correction of bias linked to the number of cells harvested in different swabs.</p><p><strong>Results: </strong>Ureaplasma was detected in 58.7% (91/155) of NSC patients: U. parvum in 30.3%, U. urealyticum in 16.1%, and mixed infection in 12.3%. It was also detected in 54.5% (170/312) of controls: U. parvum in 33.0%, U. urealyticum in 11.5%, and mixed infection in 9.9%. There were no significant differences for U. parvum, U. urealyticum, or mixed infection between the 2 groups (p > 0.05). However, both biovars were present at higher concentrations in NSC patients than in controls (p < 0.05). Using >10 copies/1000 cells as a reference, the positive rate of U. parvum in NSC patients was 16.1%, significantly higher than that in controls at 5.1% (relative risk 3.145, p < 0.05); positive rates of U. urealyticum in NSC patients and controls were 28.4% and 8.7%, respectively, with a statistically significant difference (relative risk 3.131, p < 0.05).</p><p><strong>Conclusions: </strong>Ureaplasma can adhere to host cells, colonize, internalize, and subsequently produce pathological lesions. A high density of Ureaplasma in the cervix may be associated with the aetiology of NSC.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.922696","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32499835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 29
Undetectable hepatitis C virus RNA during syphilis infection in two HIV/HCV-co-infected patients. 两名HIV/ hcv合并感染患者梅毒感染期间丙型肝炎病毒RNA检测不足。
Pub Date : 2014-09-01 Epub Date: 2014-06-16 DOI: 10.3109/00365548.2014.920102
Kirsten Salado-Rasmussen, Andreas Knudsen, Henrik Bygum Krarup, Terese Lea Katzenstein, Jan Gerstoft

Background: Treponema pallidum, the causative agent of syphilis, elicits a vigorous immune response in the infected host. This study sought to describe the impact of syphilis infection on hepatitis C virus (HCV) RNA levels in patients with HIV and chronic HCV infection.

Methods: Patients with chronic HIV/HCV and syphilis co-infection were identified by their treating physicians from 1 October 2010 to 31 December 2013. Stored plasma samples obtained before, during, and after syphilis infection were analysed for interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and IFN-γ-inducible protein 10 kDa (IP-10).

Results: Undetectable HCV RNA at the time of early latent syphilis infection was observed in 2 patients with HIV and chronic HCV infection. After treatment of the syphilis infection, HCV RNA levels increased again in patient 1, whereas patient 2 initiated HCV therapy and remained HCV RNA-negative. Available plasma samples obtained before and after the episode with undetectable HCV RNA were phylogenetically identical, making the possibility of spontaneous clearance and HCV reinfection less likely. The IL-10, TNF-α, and IP-10 levels increased at the time of syphilis diagnosis in patient 1 and decreased again after treatment of the syphilis infection.

Conclusions: We propose that T. pallidum-induced cytokine secretion resulted in an immune response hindering HCV replication during syphilis infection. We suggest that HIV/HCV-co-infected patients with unexpected undetectable HCV RNA are tested for syphilis infection and that the serological tests include both non-treponemal and treponemal tests to avoid false-positive results caused by HCV.

背景:梅毒螺旋体(Treponema pallidum)是梅毒的病原体,在被感染的宿主体内引起强烈的免疫反应。本研究旨在描述梅毒感染对HIV和慢性HCV感染患者丙型肝炎病毒(HCV) RNA水平的影响。方法:2010年10月1日至2013年12月31日,由治疗医师鉴定的慢性HIV/HCV合并梅毒患者。分析梅毒感染前、感染期间和感染后的血浆样本中白细胞介素(IL)-2、IL-4、IL-6、IL-8、IL-10、肿瘤坏死因子α (TNF-α)、干扰素γ (IFN-γ)和IFN-γ诱导蛋白10kda (IP-10)的含量。结果:2例HIV合并慢性HCV感染患者早期潜伏梅毒感染时HCV RNA未检出。在梅毒感染治疗后,患者1的HCV RNA水平再次升高,而患者2开始HCV治疗并保持HCV RNA阴性。在未检测到HCV RNA的发作前后获得的可用血浆样本在系统发育上是相同的,这使得自发清除和HCV再感染的可能性降低。患者1在梅毒诊断时IL-10、TNF-α和IP-10水平升高,在梅毒感染治疗后再次下降。结论:我们认为梅毒t诱导的细胞因子分泌导致了梅毒感染期间阻碍丙型肝炎病毒复制的免疫反应。我们建议对意外检测不到HCV RNA的HIV/HCV合并感染患者进行梅毒感染检测,血清学检测包括非密螺旋体检测和密螺旋体检测,以避免HCV引起的假阳性结果。
{"title":"Undetectable hepatitis C virus RNA during syphilis infection in two HIV/HCV-co-infected patients.","authors":"Kirsten Salado-Rasmussen,&nbsp;Andreas Knudsen,&nbsp;Henrik Bygum Krarup,&nbsp;Terese Lea Katzenstein,&nbsp;Jan Gerstoft","doi":"10.3109/00365548.2014.920102","DOIUrl":"https://doi.org/10.3109/00365548.2014.920102","url":null,"abstract":"<p><strong>Background: </strong>Treponema pallidum, the causative agent of syphilis, elicits a vigorous immune response in the infected host. This study sought to describe the impact of syphilis infection on hepatitis C virus (HCV) RNA levels in patients with HIV and chronic HCV infection.</p><p><strong>Methods: </strong>Patients with chronic HIV/HCV and syphilis co-infection were identified by their treating physicians from 1 October 2010 to 31 December 2013. Stored plasma samples obtained before, during, and after syphilis infection were analysed for interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and IFN-γ-inducible protein 10 kDa (IP-10).</p><p><strong>Results: </strong>Undetectable HCV RNA at the time of early latent syphilis infection was observed in 2 patients with HIV and chronic HCV infection. After treatment of the syphilis infection, HCV RNA levels increased again in patient 1, whereas patient 2 initiated HCV therapy and remained HCV RNA-negative. Available plasma samples obtained before and after the episode with undetectable HCV RNA were phylogenetically identical, making the possibility of spontaneous clearance and HCV reinfection less likely. The IL-10, TNF-α, and IP-10 levels increased at the time of syphilis diagnosis in patient 1 and decreased again after treatment of the syphilis infection.</p><p><strong>Conclusions: </strong>We propose that T. pallidum-induced cytokine secretion resulted in an immune response hindering HCV replication during syphilis infection. We suggest that HIV/HCV-co-infected patients with unexpected undetectable HCV RNA are tested for syphilis infection and that the serological tests include both non-treponemal and treponemal tests to avoid false-positive results caused by HCV.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.920102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32429706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. 瑞典HIV/HCV合并感染队列中HCV治疗的高接受率
Pub Date : 2014-09-01 Epub Date: 2014-07-01 DOI: 10.3109/00365548.2014.921932
Jenny Stenkvist, Ola Weiland, Anders Sönnerborg, Anders Blaxhult, Karolin Falconer

Background: HCV co-infection is a leading cause of death in HIV-positive patients. Despite a strong indication for the treatment of HCV, treatment uptake is generally lower than in HCV mono-infected patients. The aim of this study was to determine the HCV treatment uptake and to define factors associated with initiation or deferral of HCV treatment in Swedish HIV/HCV co-infected patients.

Methods: All 5315 adult HIV-positive patients in Sweden are included in the InfCare HIV database. Demographic, virologic, and treatment data for 652 HIV/HCV co-infected patients were extracted from this database in September 2010. Factors associated with initiation of interferon-based HCV treatment were analysed. Patient- and physician-reported reasons for deferring HCV treatment were investigated in a subgroup.

Results: The anti-HCV prevalence was 14% and the chronic HCV infection rate 11%. In total, 25% of HIV/HCV co-infected patients had initiated HCV treatment. HCV genotype 2 or 3, HIV transmission route other than intravenous drug use, and ongoing HIV treatment were factors associated with a higher HCV treatment rate. The main reason for not having initiated HCV treatment was intravenous drug use or alcohol abuse.

Conclusions: The 14% prevalence of anti-HCV noted in Swedish HIV-infected patients was low by international comparisons. The 25% HCV treatment rate noted in our HIV/HCV co-infected patients was high and of the same magnitude as that published for HCV mono-infected patients in Sweden. People who inject drugs had the lowest HCV treatment uptake.

背景:HCV合并感染是hiv阳性患者死亡的主要原因。尽管HCV治疗有很强的适应症,但治疗吸收量通常低于HCV单一感染患者。本研究的目的是确定瑞典HIV/HCV合并感染患者的HCV治疗接受情况,并确定与开始或推迟HCV治疗相关的因素。方法:瑞典所有5315名成年HIV阳性患者被纳入InfCare HIV数据库。2010年9月,从该数据库中提取了652例HIV/HCV合并感染患者的人口学、病毒学和治疗数据。分析与干扰素为基础的HCV治疗开始相关的因素。在一个亚组中,对患者和医生报告的推迟HCV治疗的原因进行了调查。结果:抗-HCV患病率为14%,慢性HCV感染率为11%。总共有25%的HIV/HCV合并感染患者开始了HCV治疗。HCV基因型2或3、静脉吸毒以外的HIV传播途径以及持续的HIV治疗是HCV治疗率较高的相关因素。未开始丙型肝炎治疗的主要原因是静脉吸毒或酗酒。结论:瑞典hiv感染患者中14%的抗- hcv患病率与国际比较相比较低。在我们的HIV/HCV合并感染患者中,25%的HCV治疗率很高,与瑞典发表的HCV单一感染患者的治疗率相同。注射吸毒者的丙型肝炎病毒治疗接受率最低。
{"title":"High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort.","authors":"Jenny Stenkvist,&nbsp;Ola Weiland,&nbsp;Anders Sönnerborg,&nbsp;Anders Blaxhult,&nbsp;Karolin Falconer","doi":"10.3109/00365548.2014.921932","DOIUrl":"https://doi.org/10.3109/00365548.2014.921932","url":null,"abstract":"<p><strong>Background: </strong>HCV co-infection is a leading cause of death in HIV-positive patients. Despite a strong indication for the treatment of HCV, treatment uptake is generally lower than in HCV mono-infected patients. The aim of this study was to determine the HCV treatment uptake and to define factors associated with initiation or deferral of HCV treatment in Swedish HIV/HCV co-infected patients.</p><p><strong>Methods: </strong>All 5315 adult HIV-positive patients in Sweden are included in the InfCare HIV database. Demographic, virologic, and treatment data for 652 HIV/HCV co-infected patients were extracted from this database in September 2010. Factors associated with initiation of interferon-based HCV treatment were analysed. Patient- and physician-reported reasons for deferring HCV treatment were investigated in a subgroup.</p><p><strong>Results: </strong>The anti-HCV prevalence was 14% and the chronic HCV infection rate 11%. In total, 25% of HIV/HCV co-infected patients had initiated HCV treatment. HCV genotype 2 or 3, HIV transmission route other than intravenous drug use, and ongoing HIV treatment were factors associated with a higher HCV treatment rate. The main reason for not having initiated HCV treatment was intravenous drug use or alcohol abuse.</p><p><strong>Conclusions: </strong>The 14% prevalence of anti-HCV noted in Swedish HIV-infected patients was low by international comparisons. The 25% HCV treatment rate noted in our HIV/HCV co-infected patients was high and of the same magnitude as that published for HCV mono-infected patients in Sweden. People who inject drugs had the lowest HCV treatment uptake.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.921932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32473072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: evaluation of two chemiluminescent immunoassay systems. 献血者乙型肝炎病毒、丙型肝炎病毒和人类免疫缺陷病毒的筛选试验:两种化学发光免疫测定系统的评价。
Pub Date : 2014-09-01 Epub Date: 2014-07-30 DOI: 10.3109/00365548.2014.926564
Linda Sommese, Chiara Sabia, Rossella Paolillo, Delia Parente, Maria Capuano, Carmela Iannone, Francesco Cavalca, Concetta Schiano, Maria Vasco, Maria Rosaria De Pascale, Amelia Casamassimi, Claudio Napoli

Automated chemiluminescent immunoassays (CLIAs) are useful for the detection of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus 1/2 antigen/antibodies (HIV 1/2 Ag/Ab) in blood donor screening. Eight hundred and forty serum samples were tested for hepatitis B surface antigen (HBsAg), HCV antibodies (anti-HCV), and HIV1/2 Ag/Ab in parallel using 2 different CLIAs (Abbott Architect i2000SR and Roche Cobas e411). The concordance between the 2 systems was high (Cohen's kappa 0.97 for HBsAg, 0.77 for anti-HCV, 0.92 for HIV1/2 Ag/Ab) and the specificity and the positive predictive value were comparable. Among the 12 discrepant results, 11 were false-positive and 1 (reactive by Architect) was true-positive for anti-HCV. Positivity for HBV DNA, HCV RNA, and HIV RNA was recorded in 90.9%, 38.9%, and 100% of true-positive samples, respectively. This study represents the first stringent comparison between Architect i2000SR and Cobas e411 in blood donors. We observed a good correlation and high agreement among HBV, HCV, and HIV with the 2 automated systems.

自动化学发光免疫测定法(CLIAs)可用于检测乙型肝炎病毒(HBV),丙型肝炎病毒(HCV)和人类免疫缺陷病毒1/2抗原/抗体(HIV 1/2 Ag/Ab)的献血者筛选。采用2种不同的CLIAs(雅培Architect i2000SR和罗氏Cobas e411),对840份血清样本进行乙型肝炎表面抗原(HBsAg)、丙型肝炎抗体(抗丙型肝炎抗体)和HIV1/2 Ag/Ab的平行检测。两种系统的一致性较高(HBsAg的Cohen’s kappa为0.97,anti-HCV为0.77,HIV1/2 Ag/Ab为0.92),特异性和阳性预测值具有可比性。在12个差异结果中,11个为假阳性,1个(Architect反应性)为真阳性。HBV DNA、HCV RNA和HIV RNA阳性率分别为90.9%、38.9%和100%。这项研究首次对献血者的Architect i2000SR和Cobas e411进行了严格的比较。我们观察到HBV、HCV和HIV与这两种自动化系统有很好的相关性和高度一致性。
{"title":"Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: evaluation of two chemiluminescent immunoassay systems.","authors":"Linda Sommese,&nbsp;Chiara Sabia,&nbsp;Rossella Paolillo,&nbsp;Delia Parente,&nbsp;Maria Capuano,&nbsp;Carmela Iannone,&nbsp;Francesco Cavalca,&nbsp;Concetta Schiano,&nbsp;Maria Vasco,&nbsp;Maria Rosaria De Pascale,&nbsp;Amelia Casamassimi,&nbsp;Claudio Napoli","doi":"10.3109/00365548.2014.926564","DOIUrl":"https://doi.org/10.3109/00365548.2014.926564","url":null,"abstract":"<p><p>Automated chemiluminescent immunoassays (CLIAs) are useful for the detection of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus 1/2 antigen/antibodies (HIV 1/2 Ag/Ab) in blood donor screening. Eight hundred and forty serum samples were tested for hepatitis B surface antigen (HBsAg), HCV antibodies (anti-HCV), and HIV1/2 Ag/Ab in parallel using 2 different CLIAs (Abbott Architect i2000SR and Roche Cobas e411). The concordance between the 2 systems was high (Cohen's kappa 0.97 for HBsAg, 0.77 for anti-HCV, 0.92 for HIV1/2 Ag/Ab) and the specificity and the positive predictive value were comparable. Among the 12 discrepant results, 11 were false-positive and 1 (reactive by Architect) was true-positive for anti-HCV. Positivity for HBV DNA, HCV RNA, and HIV RNA was recorded in 90.9%, 38.9%, and 100% of true-positive samples, respectively. This study represents the first stringent comparison between Architect i2000SR and Cobas e411 in blood donors. We observed a good correlation and high agreement among HBV, HCV, and HIV with the 2 automated systems.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.926564","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32544469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Hand carriage of Candida occurs at lesser rates in hospital personnel who use antimicrobial hand disinfectant. 使用抗菌手消毒剂的医护人员携带念珠菌的发生率较低。
Pub Date : 2014-09-01 Epub Date: 2014-06-23 DOI: 10.3109/00365548.2014.922694
Mustafa Yildirim, Idris Sahin, Sukru Oksuz, Irfan Sencan, Abdulkadir Kucukbayrak, Selma Cakir, Cigdem Ozaydin

Background: The hands of hospital personnel are considered to be important for colonization and infection of patients with Candida spp. The aim of this study was to evaluate the effectiveness of different hand disinfectants in reducing the carriage of Candida species on the hands of hospital personnel.

Methods: A controlled study was conducted at Duzce University School of Medicine Hospital. Eighty hospital personnel were included in the trial. Subjects were divided into 4 groups according to hand hygiene procedures: group 1, hand rubbing with alcohol-based solution; group 2, hand washing with 4% chlorhexidine gluconate; group 3, hand washing with 7.5% povidone-iodine; group 4, hand washing with plain soap and water. The hands of all participants were tested by culture with the broth wash technique.

Results: Hand carriage of Candida spp. was lower in the 4% chlorhexidine gluconate group (10.5%, p = 0.006), in the 7.5% povidone-iodine group (18.7%, p = 0.043), and in the alcohol-based hand rub group (21.1%, p = 0.048) compared to the group washing hands with plain soap and water (50%).

Conclusions: The use of hand disinfectant containing antimicrobial agents is more effective than hand washing with water and soap in reducing carriage of Candida on the hands of hospital personnel. It is recommended that hospital personnel use an antimicrobial hand disinfectant in units where there is a high risk of Candida infection.

背景:医院工作人员的手被认为是念珠菌定植和感染患者的重要因素,本研究的目的是评估不同手部消毒剂对减少医院工作人员手上念珠菌携带的有效性。方法:在杜兹大学医学院附属医院进行对照研究。80名医院工作人员参与了试验。按手卫生程序将受试者分为4组:1组,用酒精溶液搓手;第二组,用4%葡萄糖酸氯己定洗手;第三组,7.5%聚维酮碘洗手;第四组,用普通肥皂和水洗手。所有参与者的手都进行了肉汤清洗技术的培养测试。结果:4%葡萄糖酸氯己定组(10.5%,p = 0.006)、7.5%聚维酮碘组(18.7%,p = 0.043)和含酒精洗手液组(21.1%,p = 0.048)的念珠菌携带率低于普通肥皂和水洗手组(50%)。结论:使用含抗菌药物的洗手消毒剂比用水和肥皂洗手更能有效地减少医务人员手上念珠菌的携带。建议医院人员在有念珠菌感染高风险的单位使用抗菌手部消毒剂。
{"title":"Hand carriage of Candida occurs at lesser rates in hospital personnel who use antimicrobial hand disinfectant.","authors":"Mustafa Yildirim,&nbsp;Idris Sahin,&nbsp;Sukru Oksuz,&nbsp;Irfan Sencan,&nbsp;Abdulkadir Kucukbayrak,&nbsp;Selma Cakir,&nbsp;Cigdem Ozaydin","doi":"10.3109/00365548.2014.922694","DOIUrl":"https://doi.org/10.3109/00365548.2014.922694","url":null,"abstract":"<p><strong>Background: </strong>The hands of hospital personnel are considered to be important for colonization and infection of patients with Candida spp. The aim of this study was to evaluate the effectiveness of different hand disinfectants in reducing the carriage of Candida species on the hands of hospital personnel.</p><p><strong>Methods: </strong>A controlled study was conducted at Duzce University School of Medicine Hospital. Eighty hospital personnel were included in the trial. Subjects were divided into 4 groups according to hand hygiene procedures: group 1, hand rubbing with alcohol-based solution; group 2, hand washing with 4% chlorhexidine gluconate; group 3, hand washing with 7.5% povidone-iodine; group 4, hand washing with plain soap and water. The hands of all participants were tested by culture with the broth wash technique.</p><p><strong>Results: </strong>Hand carriage of Candida spp. was lower in the 4% chlorhexidine gluconate group (10.5%, p = 0.006), in the 7.5% povidone-iodine group (18.7%, p = 0.043), and in the alcohol-based hand rub group (21.1%, p = 0.048) compared to the group washing hands with plain soap and water (50%).</p><p><strong>Conclusions: </strong>The use of hand disinfectant containing antimicrobial agents is more effective than hand washing with water and soap in reducing carriage of Candida on the hands of hospital personnel. It is recommended that hospital personnel use an antimicrobial hand disinfectant in units where there is a high risk of Candida infection.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.922694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32445135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Prosthetic hip joint infection caused by non-capsulated Haemophilus influenzae. 非荚膜流感嗜血杆菌引起的人工髋关节感染。
Pub Date : 2014-09-01 Epub Date: 2014-06-11 DOI: 10.3109/00365548.2014.920101
Bo Söderquist

Haemophilus influenzae is rarely described as a causative agent of prosthetic joint infections. Here, a case of prosthetic hip joint infection caused by H. influenzae is reported. Treatment was successful, resulting in implant salvage, by debridement and antibiotic treatment with ciprofloxacin as monotherapy for 3 months.

流感嗜血杆菌很少被描述为假体关节感染的病原体。在这里,一个病例假髋关节感染引起的流感嗜血杆菌报告。治疗成功,通过清创和抗生素治疗,环丙沙星单药治疗3个月,保留种植体。
{"title":"Prosthetic hip joint infection caused by non-capsulated Haemophilus influenzae.","authors":"Bo Söderquist","doi":"10.3109/00365548.2014.920101","DOIUrl":"https://doi.org/10.3109/00365548.2014.920101","url":null,"abstract":"<p><p>Haemophilus influenzae is rarely described as a causative agent of prosthetic joint infections. Here, a case of prosthetic hip joint infection caused by H. influenzae is reported. Treatment was successful, resulting in implant salvage, by debridement and antibiotic treatment with ciprofloxacin as monotherapy for 3 months.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.920101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32413473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. 重症监护病房中产kpc肺炎克雷伯菌血流感染患者的感染危险因素和死亡率预测因素
Pub Date : 2014-09-01 Epub Date: 2014-07-14 DOI: 10.3109/00365548.2014.923106
Matthaios Papadimitriou-Olivgeris, Markos Marangos, Myrto Christofidou, Fotini Fligou, Christina Bartzavali, Eleftheria S Panteli, Sophia Vamvakopoulou, Kriton S Filos, Evangelos D Anastassiou

Background: Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections in intensive care units (ICUs) are associated with increased mortality. We aimed to determine risk factors for infection and predictors of 30-day mortality in ICU patients with KPC-Kp bloodstream infections (BSI).

Methods: During a 26-month period, patients (n = 273) who stayed more than 6 days in the ICU of the University Hospital of Patras, Greece, were divided into 2 groups, those who developed KPC-Kp BSI and those who did not. K. pneumoniae was identified by Vitek 2 technology. Antibiotic susceptibility testing was performed by agar disk diffusion method. Minimum inhibitory concentrations were determined by Etest. The presence of the blaKPC gene was confirmed by PCR. Molecular typing was performed by pulsed-field gel electrophoresis of XbaI-restricted genomic DNA. Epidemiological data were collected by patient chart review.

Results: Five patients had bacteraemia upon admission, while in 48 (17.6%) the BSI developed after 6 days of hospitalization. Risk factors for KPC-Kp BSI in the latter group were the administration of aminoglycosides, number of invasive catheters inserted after the third day, and tracheostomy. The 30-day mortality was 43.4% (23/53 patients). Multivariate analysis revealed that age, SAPS II score at onset of BSI, resistance to colistin, gentamicin, or tigecycline, and septic shock were independently associated with mortality. Treatment with at least 2 appropriate antibiotics was identified as a predictor of a good prognosis.

Conclusions: Many risk factors are involved in KPC-Kp BSI among ICU patients. The high mortality in patients with KPC-KP BSI in the ICU requires the implementation of appropriate infection control measures.

背景:产碳青霉烯酶(KPC)的肺炎克雷伯菌(KPC- kp)感染在重症监护病房(icu)与死亡率增加相关。我们的目的是确定感染的危险因素和KPC-Kp血流感染(BSI) ICU患者30天死亡率的预测因素。方法:将273例在希腊帕特雷大学医院ICU住院6天以上的患者分为2组,分别为KPC-Kp BSI组和未发生KPC-Kp BSI组。采用Vitek 2技术鉴定肺炎克雷伯菌。采用琼脂纸片扩散法进行药敏试验。最低抑菌浓度用Etest测定。PCR证实了blaKPC基因的存在。采用脉冲场凝胶电泳对xbai限制性基因组DNA进行分子分型。流行病学资料通过患者图表收集。结果:5例患者入院时出现菌血症,48例患者(17.6%)在入院后6天出现BSI。后一组KPC-Kp BSI的危险因素为氨基糖苷类药物的使用、第3天后插入导管的次数和气管切开术。30天死亡率为43.4%(23/53)。多因素分析显示,年龄、BSI发病时SAPS II评分、对粘菌素、庆大霉素或替加环素的耐药性以及感染性休克与死亡率独立相关。用至少2种适当的抗生素治疗被确定为预后良好的预测因子。结论:ICU患者KPC-Kp BSI与多种危险因素有关。ICU中KPC-KP BSI患者的高死亡率要求实施适当的感染控制措施。
{"title":"Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.","authors":"Matthaios Papadimitriou-Olivgeris,&nbsp;Markos Marangos,&nbsp;Myrto Christofidou,&nbsp;Fotini Fligou,&nbsp;Christina Bartzavali,&nbsp;Eleftheria S Panteli,&nbsp;Sophia Vamvakopoulou,&nbsp;Kriton S Filos,&nbsp;Evangelos D Anastassiou","doi":"10.3109/00365548.2014.923106","DOIUrl":"https://doi.org/10.3109/00365548.2014.923106","url":null,"abstract":"<p><strong>Background: </strong>Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections in intensive care units (ICUs) are associated with increased mortality. We aimed to determine risk factors for infection and predictors of 30-day mortality in ICU patients with KPC-Kp bloodstream infections (BSI).</p><p><strong>Methods: </strong>During a 26-month period, patients (n = 273) who stayed more than 6 days in the ICU of the University Hospital of Patras, Greece, were divided into 2 groups, those who developed KPC-Kp BSI and those who did not. K. pneumoniae was identified by Vitek 2 technology. Antibiotic susceptibility testing was performed by agar disk diffusion method. Minimum inhibitory concentrations were determined by Etest. The presence of the blaKPC gene was confirmed by PCR. Molecular typing was performed by pulsed-field gel electrophoresis of XbaI-restricted genomic DNA. Epidemiological data were collected by patient chart review.</p><p><strong>Results: </strong>Five patients had bacteraemia upon admission, while in 48 (17.6%) the BSI developed after 6 days of hospitalization. Risk factors for KPC-Kp BSI in the latter group were the administration of aminoglycosides, number of invasive catheters inserted after the third day, and tracheostomy. The 30-day mortality was 43.4% (23/53 patients). Multivariate analysis revealed that age, SAPS II score at onset of BSI, resistance to colistin, gentamicin, or tigecycline, and septic shock were independently associated with mortality. Treatment with at least 2 appropriate antibiotics was identified as a predictor of a good prognosis.</p><p><strong>Conclusions: </strong>Many risk factors are involved in KPC-Kp BSI among ICU patients. The high mortality in patients with KPC-KP BSI in the ICU requires the implementation of appropriate infection control measures.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.923106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32499837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 52
Aggregatibacter actinomycetemcomitans infection mimicking lung cancer: a case report. 模拟肺癌的聚集菌放线菌感染1例。
Pub Date : 2014-09-01 Epub Date: 2014-06-09 DOI: 10.3109/00365548.2014.920104
Melissa Matzumura-Kuan, Jeffrey Jennings

Pulmonary infections can mimic a pulmonary neoplasm. Multiple organisms, including bacteria, viruses, and fungi, can present with similar clinical, radiographic, and surgical findings as neoplastic processes. Because treatment and the prognosis are completely different, an accurate diagnosis is crucial, and lung biopsy is usually required. Aggregatibacter actinomycetemcomitans is part of the normal oral flora and is a rare cause of invasive infection due to hematogenous dissemination or aspiration, particularly infective endocarditis. We present a case of A. actinomycetemcomitans and Actinomyces co-infection that presented as a mediastinal mass, with surgical findings similar to lung malignancy but with biopsy and culture showing an infectious origin. After antibiotic treatment, follow-up images showed resolution of the mass.

肺部感染可以模拟肺部肿瘤。多种生物,包括细菌、病毒和真菌,可以表现出与肿瘤过程相似的临床、放射学和外科表现。由于治疗和预后完全不同,准确的诊断至关重要,通常需要进行肺活检。放线菌聚集菌是正常口腔菌群的一部分,是一种罕见的因血液传播或吸入性侵袭性感染的原因,特别是感染性心内膜炎。我们报告一例放线菌和放线菌共同感染的病例,表现为纵隔肿块,手术结果与肺恶性肿瘤相似,但活检和培养显示感染起源。抗生素治疗后,随访图像显示肿块的分辨率。
{"title":"Aggregatibacter actinomycetemcomitans infection mimicking lung cancer: a case report.","authors":"Melissa Matzumura-Kuan,&nbsp;Jeffrey Jennings","doi":"10.3109/00365548.2014.920104","DOIUrl":"https://doi.org/10.3109/00365548.2014.920104","url":null,"abstract":"<p><p>Pulmonary infections can mimic a pulmonary neoplasm. Multiple organisms, including bacteria, viruses, and fungi, can present with similar clinical, radiographic, and surgical findings as neoplastic processes. Because treatment and the prognosis are completely different, an accurate diagnosis is crucial, and lung biopsy is usually required. Aggregatibacter actinomycetemcomitans is part of the normal oral flora and is a rare cause of invasive infection due to hematogenous dissemination or aspiration, particularly infective endocarditis. We present a case of A. actinomycetemcomitans and Actinomyces co-infection that presented as a mediastinal mass, with surgical findings similar to lung malignancy but with biopsy and culture showing an infectious origin. After antibiotic treatment, follow-up images showed resolution of the mass.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.920104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32408701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
期刊
Scandinavian Journal of Infectious Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1